A Systematic Review on Long-Term Efficacy Outcome Measures in Crohn’s Disease Patients
Laura Janssen(Maastricht University Medical Centre), Marieke Pierik(Maastricht University Medical Centre), Adriaan A. van Bodegraven(Zuyderland Medisch Centrum), Rob H. Creemers(Zuyderland Medisch Centrum)
Cited by 14
Related Papers
IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes
|Nature Communications|2018|252
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment
|Alimentary Pharmacology & Therapeutics|2020|129
Sex-Related Differences in Patients With Inflammatory Bowel Disease: Results of 2 Prospective Cohort Studies
|Inflammatory Bowel Diseases|2018|103
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
|Alimentary Pharmacology & Therapeutics|2020|87